Employees: 753
Size Medy-Tox (086900.KS) is a South Korea Health Care company (Biotechnology) with a market value of $350M, the 438th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩68,400 on 18 Nov 2026.
Performance Over six months the shares fell 35.6%, against -31.1% for the median peer and -37.2% for the South Korea market (cap-weighted) — 8th lowest of 20 in its peer set.
Growth Revenue grew 3.1% over the last twelve months (peer median +7.2%); the operating margin is 9.6% (peer median -18.5%).
Valuation It trades at 18.1× forward earnings against a peer median of 16.2× (2nd most expensive of 4).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -7 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.7 points below its cost of capital (5.4% WACC).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩249B | ₩247B | ₩229B | ₩221B | ₩195B |
| Revenue growth | — | +8% | +3% | +13% | — |
| Gross profit | ₩152B | ₩137B | ₩132B | ₩128B | ₩124B |
| EBITDA | ₩44.2B | ₩36.6B | ₩40.3B | ₩32.7B | ₩61.8B |
| Net income | ₩19.5B | ₩16.6B | ₩17.0B | ₩9.76B | ₩37.0B |
| Free cash flow | ₩47.7B | ₩45.8B | ₩24.5B | ₩2.98B | ₩14.2B |
| Capital expenditure | ₩28.4B | ₩34.2B | ₩18.7B | ₩37.5B | ₩25.1B |
| Total debt | ₩124B | ₩76.6B | ₩87.2B | ₩82.8B | ₩121B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 086900.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.0% | -5.7% | 9th highest of 20 |
| 6-month return | -35.6% | -31.1% | 8th lowest of 20 |
| Distance from 52-week high | -51.5% | -49.8% | 10th lowest of 20 |
| Revenue growth (TTM) | +3.1% | +7.2% | 5th lowest of 16 |
| Operating margin | 9.6% | -18.5% | 5th highest of 17 |
| Forward P/E | 18.1× | 16.2× | 2nd most expensive of 4 |
| Growth the price implies (Req g, 7 yrs) | 4.7% | 36.6% | 2nd least demanding of 4 |
| Growth delivered (Del g) | +11.9% | +37.6% | 2nd lowest of 4 |
| Hurdle (Req g minus delivered) | -7.2 pp | +14.3 pp | 2nd least demanding of 4 |
| ROIC minus cost of capital | -1.7 pp | -9.4 pp | 4th highest of 16 |
| EV / EBITDA | 12.4× | 13.2× | 4th cheapest of 7 |
| Net debt / EBITDA | 1.7× | -2.9× | most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Medy-Tox 086900.KS | South Korea | $350M | -36% | +3% | 10% | 18.1× | 4.7% | +11.9% |
| Aspen Neuroscience ASPE | United States | $349M | n/a | n/a | n/a | n/a | n/a | n/a |
| CorMedix CRMD | United States | $358M | -43% | +92% | 39% | n/a | n/a | n/a |
| Lyell Immunopharma LYEL | United States | $341M | -19% | -63% | -1,388,360% | n/a | n/a | n/a |
| GI Innovation 358570.KS | South Korea | $339M | -47% | +1,527% | -918% | n/a | n/a | n/a |
| Contineum Therapeutics CTNM | United States | $363M | -31% | n/a | n/a | n/a | n/a | n/a |
| Larimar Therapeutics LRMR | United States | $337M | -9% | n/a | n/a | n/a | n/a | n/a |
| Onconic Therapeutics 476060.KS | South Korea | $368M | -49% | +179% | 21% | n/a | 0.6% | +725.2% |
| Medtide 3880.HK | Hong Kong | $331M | -17% | +14% | 36% | 10.5× | n/a | n/a |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $370M | -31% | 0% | -4% | n/a | n/a | n/a |
| Laekna 2105.HK | Hong Kong | $326M | -53% | n/a | -57% | n/a | n/a | n/a |
| C4 Therapeutics CCCC | United States | $325M | -25% | +7% | -316% | n/a | n/a | n/a |
| PureTech Health PRTC.L | United Kingdom | $378M | -15% | -4% | -1,617% | n/a | n/a | n/a |
| AP Biosciences 6945.TWO | Taiwan | $321M | -31% | n/a | n/a | n/a | n/a | n/a |
| Alector ALEC | United States | $383M | +21% | +151% | 25% | n/a | n/a | n/a |
| IMPACT Therapeutics 7630.HK | Hong Kong | $319M | -79% | +395% | -173% | n/a | n/a | n/a |
| Hubei Goto Biopharm 300966.SZ | China | $386M | -16% | +6% | -10% | n/a | n/a | n/a |
| Polynovo PNV.AX | Australia | $388M | -34% | +13% | 5% | 84.0× | 51.9% | +37.6% |
| ProKidney PROK | United States | $314M | -38% | +4% | -24,830% | n/a | n/a | n/a |
| Beijing Kawin Technology Share-Holding 688687.SS | China | $391M | -20% | +6% | -2% | 16.2× | 36.6% | +8.9% |
| Wuhan Hiteck Biological Pharma 300683.SZ | China | $395M | -41% | -30% | -27% | n/a | n/a | n/a |